Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(4S)-4-(2-naphthylmethyl)-D-glutamic acid is a synthetic small molecule derivative of D-glutamic acid in which the side chain at the 4-position is substituted with a 2-naphthylmethyl group. It belongs to the class of benzenoids and naphthalene derivatives. The compound has not been approved for any therapeutic use and is considered experimental. There are no known clinical trials or indications for this molecule as of now. Its mechanism of action, pharmacological activity, and potential therapeutic applications have not been established in published literature[1][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (4S)-4-(2-naphthylmethyl)-D-glutamic acid.